MIDLAND, Mich., Jan. 20 /PRNewswire/ -- Dowpharma, a business unit of The Dow Chemical Company, is pleased to introduce the next generation of microbial expression technologies for the production of recombinant proteins. This new technology platform is built around specially designed strains of Pseudomonas fluorescens that increase cellular expression while maintaining critical solubility and activity characteristics of recombinant proteins. Dowpharma has demonstrated that this technology delivers significant benefits not typically realized using other microbial host cell systems.
"We have found that this system consistently outperformed existing microbial expression platforms and also delivers advantages in recovery and purification," says Nick Hyde, business director, Dowpharma. "This improved performance will positively impact our biopharmaceutical customers' bottom lines.
"Furthermore, because we have fully sequenced, annotated and researched the genome, we can quickly and easily modify the strains to increase the expression of a particular client's biotherapeutic. This will help speed our customers to the clinic with a reliable, robust manufacturing program."
Fermentation using Dow's Pseudomonas fluorescens expression technology is carried out at high cell density using only soluble, defined mineral salts media containing no animal-derived components or antibiotics. Fermentation is also readily scalable.
In the coming year, Dowpharma will be presenting data at conferences in both the U.S. and Europe, describing the performance of P. fluorescens in the production of therapeutic proteins.
For further information on how this next generation technology can benefit your biopharmaceutical program, please contact Patrick Lucy, Director of Business Development, Dowpharma, Biopharmaceutical Contract Manufacturing Services, at email@example.com, or by visiting our website at http://www.dowpharma.com/.
Dowpharma serves the pharmaceutical and biopharmaceutical industries with innovative technology, products, and services for clients in drug discovery, development, manufacturing, and delivery. Dowpharma combines the resources and capabilities of several entities to create a single, market-focused organization with broad service and support capabilities for large and emerging pharmaceutical companies.
Dowpharma services include process development, route selection, methods development, and associated analytical services, as well as manufacturing and scale-up from the bench, through clinical trials, to commercial launch. Dowpharma currently manufactures small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, oligonucleotides, cGMP polymers, and proteins from microbial fermentation.
Dowpharma draws upon a 20 year history of excellent cGMP regulatory compliance in the organic synthesis of APIs and pharmaceutical intermediates with the ability to provide client support in filing and validation strategies. The business also manufactures a long list of scaffolds and fine chemicals of interest to the drug development community. Dowpharma operates research, process development, and manufacturing facilities in North America and Europe.
For more information on Dowpharma: http://www.dowpharma.com/
About The Dow Chemical Company
Dow is a leading science and technology company that provides innovative chemical, plastic, and agricultural products and services to many essential consumer markets. With annual sales of $28 billion, Dow serves customers in more than 170 countries and a wide range of markets that are vital to human progress, including food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of Sustainable Development, Dow and its approximately 50,000 employees seek to balance economic, environmental, and social responsibilities.